Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Multitude Therapeutics (United States)
Homepage:
en.multitudetherapeutics.com
Alternate names:
Multitude Therapeutics,
Multitude Therapeutics, Inc.
ROR:
03gtk6197
OpenAlex ID:
I4405284409
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
2019
·
Guoyun Zhu
, Davide Foletti
, et al.
·
Scientific Reports
·
81
PDF
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
2019
·
Maria José Costa
, Jyothirmayee Kudaravalli
, et al.
·
Scientific Reports
·
25
PDF
A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023
·
Jing Shi
, Tao Jiao
, et al.
·
Cancer Research
·
20
PDF
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
2019
·
Guoyun Zhu
, Davide Foletti
, et al.
·
Scientific Reports
·
8
PDF
MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma
2025
·
Fenghao Zhang
, Haizhen Du
, et al.
·
Journal of Translational Medicine
·
6
PDF
CUSP06, a Novel CDH6-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Multiple CDH6-Expressing Human Cancer Models
2025
·
Wei Lu
, Jing Shi
, et al.
·
Pharmaceutics
·
4
PDF
A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.
2025
·
Charlotte Rose Lemech
, Warren Lance Joubert
, et al.
·
Journal of Clinical Oncology
·
4
Cell-autonomous targeting of arabinogalactan by host immune factors inhibits mycobacterial growth
2024
·
Lianhua Qin
, Junfang Xu
, et al.
·
eLife
·
4
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.
2024
·
Jim Coward
, Ganessan Kichenadasse
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Pancancer pro-angiogenic atlas unravels tumor-educated pericyte-augmented anti-angiogenic resistance
2026
·
Yongqiang Zheng
, Hui Sun
, et al.
·
中国科学通报:英文版
·
2
Antibody-mediated co-delivery of programmable drug combinations
2024
·
Xun Meng
, Wenlong Sun
, et al.
·
Research Square
·
2
PDF
997P Ongoing phase I trial results of AMT-253, a first-in-class MUC18-targeting antibody-drug conjugate in patients with melanoma and other advanced solid tumors
2025
·
J. Guo
, C. Cui
, et al.
·
Annals of Oncology
·
1
922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors
2025
·
Z. Song
, J. Park
, et al.
·
Annals of Oncology
·
1
Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers
2026
·
Ying‐nan Wang
, Dan‐yun Ruan
, et al.
·
Advanced Science
PDF
112P Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors
2026
·
C. Lemech
, R-H. Xu
, et al.
·
Annals of Oncology
Cell-autonomous targeting of arabinogalactan by host immune factors inhibits mycobacterial growth
2024
·
Lianhua Qin
, Junfang Xu
, et al.
·
eLife
Show more works
View as search
Works count:
17
Citation count:
161
Year
Topic
Type